Let’s find a uterine or endometrial cancer clinical trial for you
Let’s find a uterine or endometrial cancer clinical trial for you
North is the fastest way to discover and match with one of the 506 uterine and endometrial cancer trials open in the U.S.
North is the fastest way to discover and match with one of the 506 uterine and endometrial cancer trials open in the U.S.
How North Works
1
5-10 minute health
history intake
5-10 minute health
history intake
2
We’ll send you personalized match results in 1-2 days
We’ll send you personalized match results in 1-2 days
3
We'll connect you with clinical trial coordinators
We'll connect you with clinical trial coordinators
1
5-10 minute health
history intake
2
We’ll send you personalized
match results in 1-2 days
3
We'll connect you with
clinical trial coordinators
Take the next step
Explore trials near you
0
0
Uterine and endometrial cancer trials in the U.S.
0
0
Uterine cancer U.S. clinical trials
0
0
Endometrial U.S. clinical trials
North's expert research advisors
Dr. Mike Gibson
Dr. Mike Gibson
MD, PhD, Division of Hematology and
Oncology, Vanderbilt-Ingram Cancer Center
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram
Cancer Center
Dr. Carol Tweed
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Board Certified MD, Hematology and
Medical Oncology, Annapolis, Maryland
Holly Hoefer
Holly Hoefer
VP Patient Engagement, Helios
Clinical Research
Dr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
ResearchDr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
ResearchDr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
ResearchDr. Mike Gibson
MD, PhD, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center
Dr. Carol Tweed
Board Certified MD, Hematology and Medical Oncology, Annapolis, Maryland
Holly Hoefer
VP Patient Engagement,
Helios Clinical
Research
Questions about uterine or endometrial cancer clinical trials?
What are the new treatments for endometrial cancer in 2025?
New and growing treatments for endometrial cancer (2025):
Immunotherapy / checkpoint inhibitors — increasingly used in tumors with mismatch-repair deficiency or microsatellite instability (MSI).
Targeted / molecular therapies — drugs tailored to a tumor’s genetic/molecular profile instead of “one-size-fits-all” chemotherapy.
Combination approaches — e.g., immunotherapy + hormone or targeted therapy, aiming for better effectiveness with fewer side effects.
Personalized treatment planning — physicians increasingly use molecular/genetic tumor testing to guide therapy decisions.
What are the new treatments for endometrial cancer in 2025?
New and growing treatments for endometrial cancer (2025):
Immunotherapy / checkpoint inhibitors — increasingly used in tumors with mismatch-repair deficiency or microsatellite instability (MSI).
Targeted / molecular therapies — drugs tailored to a tumor’s genetic/molecular profile instead of “one-size-fits-all” chemotherapy.
Combination approaches — e.g., immunotherapy + hormone or targeted therapy, aiming for better effectiveness with fewer side effects.
Personalized treatment planning — physicians increasingly use molecular/genetic tumor testing to guide therapy decisions.
What are the new treatments for endometrial cancer in 2025?
New and growing treatments for endometrial cancer (2025):
Immunotherapy / checkpoint inhibitors — increasingly used in tumors with mismatch-repair deficiency or microsatellite instability (MSI).
Targeted / molecular therapies — drugs tailored to a tumor’s genetic/molecular profile instead of “one-size-fits-all” chemotherapy.
Combination approaches — e.g., immunotherapy + hormone or targeted therapy, aiming for better effectiveness with fewer side effects.
Personalized treatment planning — physicians increasingly use molecular/genetic tumor testing to guide therapy decisions.
How quickly does uterine cancer spread?
Uterine (endometrial) cancer is usually slow-growing, especially in its early forms. Most cases stay confined to the uterus for a long time.
How fast it spreads
Type 1 (most common):
Typically slow, spreading over months to years. Often caught early.Type 2 (aggressive subtypes like serous or clear cell):
Can spread more quickly, sometimes over weeks to months, especially to lymph nodes or the abdomen.
Key factors that affect speed
Tumor type and grade
Depth of invasion into the uterine wall
Lymphovascular invasion
Patient age and overall health
Simple takeaway:
Most uterine cancers spread slowly, but certain aggressive types can spread much faster.
How quickly does uterine cancer spread?
Uterine (endometrial) cancer is usually slow-growing, especially in its early forms. Most cases stay confined to the uterus for a long time.
How fast it spreads
Type 1 (most common):
Typically slow, spreading over months to years. Often caught early.Type 2 (aggressive subtypes like serous or clear cell):
Can spread more quickly, sometimes over weeks to months, especially to lymph nodes or the abdomen.
Key factors that affect speed
Tumor type and grade
Depth of invasion into the uterine wall
Lymphovascular invasion
Patient age and overall health
Simple takeaway:
Most uterine cancers spread slowly, but certain aggressive types can spread much faster.
How quickly does uterine cancer spread?
Uterine (endometrial) cancer is usually slow-growing, especially in its early forms. Most cases stay confined to the uterus for a long time.
How fast it spreads
Type 1 (most common):
Typically slow, spreading over months to years. Often caught early.Type 2 (aggressive subtypes like serous or clear cell):
Can spread more quickly, sometimes over weeks to months, especially to lymph nodes or the abdomen.
Key factors that affect speed
Tumor type and grade
Depth of invasion into the uterine wall
Lymphovascular invasion
Patient age and overall health
Simple takeaway:
Most uterine cancers spread slowly, but certain aggressive types can spread much faster.
What is the end stage of uterine cancer?
The end stage of uterine (endometrial) cancer is Stage IV (Stage 4).
This means the cancer has spread beyond the pelvis to distant organs.
What Stage IV typically includes
Spread to the bladder or bowel (Stage IVA)
Spread to distant organs such as lungs, liver, or bones (Stage IVB)
What it usually means clinically
Surgery is often no longer curative
Treatment focuses on controlling cancer, relieving symptoms, and maintaining quality of life
Options may include chemotherapy, hormonal therapy, immunotherapy, or palliative care depending on health and tumor type
What is the end stage of uterine cancer?
The end stage of uterine (endometrial) cancer is Stage IV (Stage 4).
This means the cancer has spread beyond the pelvis to distant organs.
What Stage IV typically includes
Spread to the bladder or bowel (Stage IVA)
Spread to distant organs such as lungs, liver, or bones (Stage IVB)
What it usually means clinically
Surgery is often no longer curative
Treatment focuses on controlling cancer, relieving symptoms, and maintaining quality of life
Options may include chemotherapy, hormonal therapy, immunotherapy, or palliative care depending on health and tumor type
What is the end stage of uterine cancer?
The end stage of uterine (endometrial) cancer is Stage IV (Stage 4).
This means the cancer has spread beyond the pelvis to distant organs.
What Stage IV typically includes
Spread to the bladder or bowel (Stage IVA)
Spread to distant organs such as lungs, liver, or bones (Stage IVB)
What it usually means clinically
Surgery is often no longer curative
Treatment focuses on controlling cancer, relieving symptoms, and maintaining quality of life
Options may include chemotherapy, hormonal therapy, immunotherapy, or palliative care depending on health and tumor type
What percentage of endometrial cancer patients have recurrence?
How often endometrial cancer comes back:
Overall recurrence is about 15–20%.
A large recent study across stages I–III found 17.6% recurrence.
Low-risk early-stage disease may recur in only ~8% of cases.
Most recurrences happen within the first 2–3 years after treatment.
Risk varies based on stage, tumor grade, depth of invasion, and cancer subtype.
Sources:
ASCO: Overall recurrence estimates
Frontiers in Oncology (2024): 17.6% recurrence across stages I–III
PMC: Low-risk early-stage recurrence (~8%)
ACR / clinical follow-up guidelines: Recurrences typically within 2–3 years
PMC: Pathologic features influencing recurrence
What percentage of endometrial cancer patients have recurrence?
How often endometrial cancer comes back:
Overall recurrence is about 15–20%.
A large recent study across stages I–III found 17.6% recurrence.
Low-risk early-stage disease may recur in only ~8% of cases.
Most recurrences happen within the first 2–3 years after treatment.
Risk varies based on stage, tumor grade, depth of invasion, and cancer subtype.
Sources:
ASCO: Overall recurrence estimates
Frontiers in Oncology (2024): 17.6% recurrence across stages I–III
PMC: Low-risk early-stage recurrence (~8%)
ACR / clinical follow-up guidelines: Recurrences typically within 2–3 years
PMC: Pathologic features influencing recurrence
What percentage of endometrial cancer patients have recurrence?
How often endometrial cancer comes back:
Overall recurrence is about 15–20%.
A large recent study across stages I–III found 17.6% recurrence.
Low-risk early-stage disease may recur in only ~8% of cases.
Most recurrences happen within the first 2–3 years after treatment.
Risk varies based on stage, tumor grade, depth of invasion, and cancer subtype.
Sources:
ASCO: Overall recurrence estimates
Frontiers in Oncology (2024): 17.6% recurrence across stages I–III
PMC: Low-risk early-stage recurrence (~8%)
ACR / clinical follow-up guidelines: Recurrences typically within 2–3 years
PMC: Pathologic features influencing recurrence
Where does endometrial cancer metastasize to first?
Most often, endometrial cancer spreads first to nearby pelvic structures and lymph nodes.
Typical early metastatic sites include:
1. Pelvic and para-aortic lymph nodes — the most common first sites.
2. Local pelvic organs — cervix, vagina, bladder, rectum.
3. Peritoneum — including the omentum.
4. Lungs — the most common distant metastatic site when it spreads outside the abdomen.
Less common: liver, bones, brain.
Where does endometrial cancer metastasize to first?
Most often, endometrial cancer spreads first to nearby pelvic structures and lymph nodes.
Typical early metastatic sites include:
1. Pelvic and para-aortic lymph nodes — the most common first sites.
2. Local pelvic organs — cervix, vagina, bladder, rectum.
3. Peritoneum — including the omentum.
4. Lungs — the most common distant metastatic site when it spreads outside the abdomen.
Less common: liver, bones, brain.
Where does endometrial cancer metastasize to first?
Most often, endometrial cancer spreads first to nearby pelvic structures and lymph nodes.
Typical early metastatic sites include:
1. Pelvic and para-aortic lymph nodes — the most common first sites.
2. Local pelvic organs — cervix, vagina, bladder, rectum.
3. Peritoneum — including the omentum.
4. Lungs — the most common distant metastatic site when it spreads outside the abdomen.
Less common: liver, bones, brain.
How North Helps
Highly curated trial matches only
Highly curated trial matches only
Most trial finders ask you to do the work of searching and filtering for a match.
Most trial finders ask you to do the work of searching and filtering for a match.
Less jargon, more real talk
Less jargon, more real talk
We translate matches from medical-speak into plain English so that you can understand them.
We translate matches from medical-speak into plain English so that you can understand them.
Human introductions to sites
Human introductions to sites
Instead of cold referrals, we make personal introductions to site coordinators near you.
Instead of cold referrals, we make personal introductions to site coordinators near you.
Why consider a trial?
Access new treatments
Access new treatments
Try promising therapies not yet available outside of the trial.
Try promising therapies not yet available outside of the trial.
Advance cancer research
Advance cancer research
Help move science forward for future patients like you.
Help move science forward for future patients like you.
Understand your options
Understand your options
Explore the possibilities before making treatment decisions.
Explore the possibilities before making treatment decisions.
Questions about North
How is North different from other cancer trial finders?
North makes it easy to find cancer clinical trials that actually fit you. Instead of long lists and medical jargon, our platform takes you through a short and simple health history intake and shows only the trials you’re likely eligible for—near where you live. You can complete matching online or by phone, and if there’s a fit, we connect you directly to the enrolling site. It’s fast, private, and built to help you explore every treatment option available to you.
How is North different from other cancer trial finders?
North makes it easy to find cancer clinical trials that actually fit you. Instead of long lists and medical jargon, our platform takes you through a short and simple health history intake and shows only the trials you’re likely eligible for—near where you live. You can complete matching online or by phone, and if there’s a fit, we connect you directly to the enrolling site. It’s fast, private, and built to help you explore every treatment option available to you.
How is North different from other cancer trial finders?
North makes it easy to find cancer clinical trials that actually fit you. Instead of long lists and medical jargon, our platform takes you through a short and simple health history intake and shows only the trials you’re likely eligible for—near where you live. You can complete matching online or by phone, and if there’s a fit, we connect you directly to the enrolling site. It’s fast, private, and built to help you explore every treatment option available to you.
How much does North cost to use as a patient?
North is free to you, forever. Our trial platform is funded by clinical trial sponsors and sites, so there's no cost to the patient. We're dedicated to matching you with trials that prioritize your needs. Once you've been successfully matched to a trial, the study treatment are provided at no cost to you and you will, in most cases, be reimbursed for study-related expenses.
How much does North cost to use as a patient?
North is free to you, forever. Our trial platform is funded by clinical trial sponsors and sites, so there's no cost to the patient. We're dedicated to matching you with trials that prioritize your needs. Once you've been successfully matched to a trial, the study treatment are provided at no cost to you and you will, in most cases, be reimbursed for study-related expenses.
How much does North cost to use as a patient?
North is free to you, forever. Our trial platform is funded by clinical trial sponsors and sites, so there's no cost to the patient. We're dedicated to matching you with trials that prioritize your needs. Once you've been successfully matched to a trial, the study treatment are provided at no cost to you and you will, in most cases, be reimbursed for study-related expenses.
How often is trial information updated on North?
Trials on North are updated every day to make sure you’re seeing studies that are currently enrolling and reflect the latest eligibility criteria from sponsors and sites. Our daily refresh keeps trial details accurate, so you never waste time on studies that have closed or changed.
How often is trial information updated on North?
Trials on North are updated every day to make sure you’re seeing studies that are currently enrolling and reflect the latest eligibility criteria from sponsors and sites. Our daily refresh keeps trial details accurate, so you never waste time on studies that have closed or changed.
How often is trial information updated on North?
Trials on North are updated every day to make sure you’re seeing studies that are currently enrolling and reflect the latest eligibility criteria from sponsors and sites. Our daily refresh keeps trial details accurate, so you never waste time on studies that have closed or changed.
What types of trials does North have access to?
North has access to over 7,000 cancer clinical trials across leading research networks and hospitals in the U.S. This includes studies for both common and rare cancers, such as lung (small cell and non-small cell), breast (HER2-positive, triple-negative, metastatic), kidney (renal cell carcinoma), colorectal, prostate, and other solid tumors.
These trials cover multiple phases—from early-stage studies testing new therapies to large-scale Phase 3 trials comparing the latest immunotherapies, targeted drugs, and combination treatments to standard care. North also connects patients to precision medicine trials, which match treatments based on a tumor’s genetic makeup, helping more people access cutting-edge options tailored to their specific cancer.
What types of trials does North have access to?
North has access to over 7,000 cancer clinical trials across leading research networks and hospitals in the U.S. This includes studies for both common and rare cancers, such as lung (small cell and non-small cell), breast (HER2-positive, triple-negative, metastatic), kidney (renal cell carcinoma), colorectal, prostate, and other solid tumors.
These trials cover multiple phases—from early-stage studies testing new therapies to large-scale Phase 3 trials comparing the latest immunotherapies, targeted drugs, and combination treatments to standard care. North also connects patients to precision medicine trials, which match treatments based on a tumor’s genetic makeup, helping more people access cutting-edge options tailored to their specific cancer.
What types of trials does North have access to?
North has access to over 7,000 cancer clinical trials across leading research networks and hospitals in the U.S. This includes studies for both common and rare cancers, such as lung (small cell and non-small cell), breast (HER2-positive, triple-negative, metastatic), kidney (renal cell carcinoma), colorectal, prostate, and other solid tumors.
These trials cover multiple phases—from early-stage studies testing new therapies to large-scale Phase 3 trials comparing the latest immunotherapies, targeted drugs, and combination treatments to standard care. North also connects patients to precision medicine trials, which match treatments based on a tumor’s genetic makeup, helping more people access cutting-edge options tailored to their specific cancer.
Will my information be kept secure and private?
Your privacy and confidentiality are our priority. During your intake, we'll ask you about your cancer diagnosis, any treatment plans or previous treatments, and whether you have any specific markers we should know about. Your personal information will be protected in compliance with relevant laws, and in a manner explained in the informed consent document. We'll never share your information with clinical trials without your consent.
Will my information be kept secure and private?
Your privacy and confidentiality are our priority. During your intake, we'll ask you about your cancer diagnosis, any treatment plans or previous treatments, and whether you have any specific markers we should know about. Your personal information will be protected in compliance with relevant laws, and in a manner explained in the informed consent document. We'll never share your information with clinical trials without your consent.
Will my information be kept secure and private?
Your privacy and confidentiality are our priority. During your intake, we'll ask you about your cancer diagnosis, any treatment plans or previous treatments, and whether you have any specific markers we should know about. Your personal information will be protected in compliance with relevant laws, and in a manner explained in the informed consent document. We'll never share your information with clinical trials without your consent.
